The global inhaler corticosteroid device market is expected to grow during the forecast period (2018 to 2023) at a CAGR of ~ 6.2 %.
Asthma is a disease of the entire respiratory tract, including large, intermediate and small airways. Asthma led to inflammation and obstruction of respiratory tract. Patients have various treatment options for asthma, particularly for young and elderly patients. Hence this has led to significant interest on the part of the inhaler device which is easy to use. Inhaled corticosteroid is the most commonly used tool for the treatment of asthma. As with increasing pollution and increasing incidences of asthma, many companies are engaged in the development of new inhaler corticosteroid devices. Hence this factor is responsible for the growth of the inhaled corticosteroid device market.
However, the high cost of treatment, misuse of funding and lack of awareness are some of the factors which are hampering the growth of the market during the forecast period.
Segmentation
The global inhaler corticosteroid device market is segmented into types of steroid inhalers, applications, and end-users. Based on types of steroid inhaler the market is segmented into beclomethasone dipropionate, budesonide, fluticasone inhaler powder, mometasone. On the basis of application, inhaler corticosteroid device market is segmented into asthma and COPD (chronic obstructive pulmonary disease), and other respiratory diseases. Based on end-user the market is segmented into hospitals, clinics, and respiratory care centers.
Key players
Some of the key players in the global inhaler corticosteroid device market are Plumage Therapeutics LLP, Pearl Therapeutic Inc, Teijin LTD, Glaxo’s Advair, LIYEN, Inc, Amgen Inc, Kos Pharmaceutical, Inc, and Teva Pharmaceutical.
Global Inhaler Corticosteroid Device Market, by Steroid Inhaler Types
Global Inhaler Corticosteroid Device Market, by Application
Global Inhaler Corticosteroid Device Market, by End-User